{"id":50626,"date":"2018-09-21T01:00:00","date_gmt":"2018-09-26T02:10:58","guid":{"rendered":"http:\/\/www.05921.net\/index.php\/2018\/09\/26\/%e4%b9%85%e7%97%85%e6%88%90%e5%8c%bb%ef%bc%9f%e6%82%a3%e8%80%85%e8%87%aa%e8%a1%8c%e8%81%94%e7%94%a8%e9%9d%b6%e5%90%91%e8%8d%af%e8%ba%ab%e4%ba%a1%ef%bc%81\/"},"modified":"2018-09-26T10:10:59","modified_gmt":"2018-09-26T02:10:59","slug":"%e4%b9%85%e7%97%85%e6%88%90%e5%8c%bb%ef%bc%9f%e6%82%a3%e8%80%85%e8%87%aa%e8%a1%8c%e8%81%94%e7%94%a8%e9%9d%b6%e5%90%91%e8%8d%af%e8%ba%ab%e4%ba%a1%ef%bc%81","status":"publish","type":"post","link":"https:\/\/www.05921.net\/index.php\/50626\/","title":{"rendered":"\u4e45\u75c5\u6210\u533b\uff1f\u60a3\u8005\u81ea\u884c\u8054\u7528\u9776\u5411\u836f\u8eab\u4ea1\uff01"},"content":{"rendered":"
\n
<\/section>\n

\u4e00\u4f4d\u610f\u8bc6\u4e0d\u6e05\uff0c\u80f8\u95f7\u618b\u6c14\uff0c\u5168\u8eab\u76ae\u80a4\u51fa\u73b0\u5927\u9762\u79ef\u6697\u7d2b\u7ea2\u8272\u7600\u6591\u7684\u60a3\u8005\u6765\u5230\u4e86\u6025\u8bca\u79d1\u3002<\/span><\/p>\n


<\/p>\n

\u8be2\u95ee\u75c5\u53f2\u53d1\u73b0\uff0c\u65e2\u5f80\u6709\u80ba\u817a\u764c\u8111\u90e8\u8f6c\u79fb\uff0c\u672f\u540e\u6062\u590d\u826f\u597d\u5374\u672a\u80fd\u9075\u533b\u5631\u4e88\u4ee5\u6b63\u89c4\u7684\u6297\u80bf\u7624\u6cbb\u7597\uff0c\u590d\u67e5\u540e\u53d1\u73b0\u75c5\u7076\u8fdb\u5c55\uff0c\u7adf\u5728\u5fae\u4fe1\u7fa4\u804a\u75c5\u53cb\u7684\u5efa\u8bae\u4e0b\u81ea\u884c\u8bbe\u5b9a\u6240\u8c13\u7684\u300c\u53cc\u9776\u300d\u65b9\u6848\uff01<\/span><\/p>\n


<\/p>\n


<\/p>\n

\u30fb\u30fb\u30fb<\/span><\/strong><\/strong><\/span><\/p>\n


<\/span><\/strong><\/strong><\/span><\/p>\n

\u75c5\u4f8b\u4ecb\u7ecd<\/strong><\/span><\/p>\n


<\/p>\n

\n
\n
\n
\n

\u57fa\u672c\u4fe1\u606f<\/span><\/strong><\/span><\/p>\n


<\/p>\n

\u60a3\u8005\u7537\uff0c60\u5c81\u3002
<\/span><\/p>\n


<\/p>\n

\u4e3b\u8bc9<\/span><\/strong><\/span><\/p>\n


<\/p>\n

\u56e0\u300c \u95f4\u6b47\u6027\u53d1\u70ed\u4f34\u610f\u8bc6\u4e0d\u6e05\u3001\u55dc\u7761\u548c\u80f8\u95f7\u618b\u6c14\u75c7\u72b6\uff0c\u8eaf\u5e72\u56db\u80a2\u51fa\u73b0\u5927\u9762\u79ef\u7247\u72b6\u7ea2\u8272\u7600\u6591 \u300d\u4e8e\u6211\u9662\u5c31\u8bca\u3002<\/span><\/p>\n


<\/p>\n

\u75c5\u53f2\u53ca\u67e5\u4f53<\/span><\/strong>
<\/span><\/span><\/p>\n


<\/p>\n

\u4e09\u5e74\u524d\u56e0\u300c \u53f3\u4fa7\u80a2\u4f53\u4f53\u529b\u51cf\u5f31 1 \u6708\u4f34\u52a0\u91cd 1 \u5468 \u300d\u884c\u53f3\u4fa7\u4e2d\u592e\u533a\u8111\u5360\u4f4d\u6027\u75c5\u53d8\u5207\u9664\u672f\uff0c\u672f\u540e\u75c5\u7406\u63d0\u793a\u53f3\u80ba\u817a\u764c\u8111\u8f6c\u79fb\uff0c\u57fa\u56e0\u68c0\u6d4b\u672a\u89c1\u660e\u786e\u9776\u70b9\uff0c\u672f\u540e\u6062\u590d\u826f\u597d\u3002\u51fa\u9662\u540e\u60a3\u8005\u672a\u9075\u533b\u5631\u4e88\u4ee5\u6b63\u89c4\u6297\u80bf\u7624\u6cbb\u7597\u3002<\/span><\/p>\n


<\/p>\n

2018 \u5e74 5 \u6708\u590d\u67e5\u53f3\u80ba\u90e8\u80bf\u7624\u75c5\u7076\u8f83\u524d\u660e\u663e\u8fdb\u5c55\uff0c\u9042\u4e8e 6 \u6708\u7ecf\u5fae\u4fe1\u7fa4\u804a\u4e2d\u7684\u75c5\u53cb\u4ecb\u7ecd\u5f00\u59cb\u53e3\u670d\u5384\u6d1b\u66ff\u5c3c\u548c\u5361\u535a\u66ff\u5c3c\uff0c\u81ea\u884c\u8bbe\u5b9a\u6240\u8c13\u7684\u300c \u53cc\u9776 \u300d\u65b9\u6848:\u6bcf 3 \u5929\u4e3a\u4e00\u4e2a\u670d\u836f\u5468\u671f\uff0c\u5171 3 \u4e2a\u5468\u671f\u3002\u5384\u6d1b\u66ff\u5c3c 150  mg \u4e00\u5929\u4e00\u6b21\uff0c\u5361\u535a\u66ff\u5c3c 50 mg \u6bcf 2\uff5e3 \u5929\u4e00\u6b21\u3002<\/span><\/p>\n


<\/p>\n

\u670d\u836f\u540e\u7b2c 6 \u5929\u56db\u80a2\u51fa\u73b0\u5c11\u91cf\u6563\u53d1\u7ea2\u8272\u76ae\u75b9\uff0c\u5c24\u4ee5\u4e0b\u80a2\u591a\u89c1\uff0c\u672a\u91cd\u89c6\uff0c\u540e\u7ee7\u7eed\u53e3\u670d\u3002\u670d\u836f\u7b2c 9 \u5929\u51fa\u73b0\u95f4\u6b47\u6027\u53d1\u70ed\uff0c\u4f53\u6e29\u6700\u9ad8 39.7 \u2103\uff0c\u4f34\u610f\u8bc6\u4e0d\u6e05\u3001\u55dc\u7761\u548c\u80f8\u95f7\u618b\u6c14\u75c7\u72b6\uff0c\u8eaf\u5e72\u56db\u80a2\u51fa\u73b0\u5927\u9762\u79ef\u7247\u72b6\u7ea2\u8272\u7600\u6591\u3002\u67e5\u4f53\u89c1\u5168\u8eab\u76ae\u80a4\u53ef\u89c1\u5927\u9762\u79ef\u6697\u7d2b\u7ea2\u8272\u7600\u6591\uff0c\u538b\u4e4b\u4e0d\u892a\u8272\uff0c\u53cc\u4e0a\u80a2\u4f38\u4fa7\u5c11\u91cf\u9488\u5c16\u6837\u5927\u5c0f\u6de1\u9ec4\u8272\u8113\u75b1\u3002\u53cc\u4fa7\u77b3\u5b54\u76f4\u63a5\u548c\u95f4\u63a5\u5bf9\u5149\u53cd\u5c04\u8fdf\u949d\uff0c\u53f3\u80ba\u4e0a\u53f6\u672a\u95fb\u53ca\u547c\u5438\u97f3\uff0c\u53cc\u80ba\u4e0b\u53f6\u542c\u8bca\u53ef\u95fb\u53ca\u53cc\u76f8\u6e7f\u7f57\u97f3\u3002\u53cc\u4e0b\u80a2\u53ef\u53ca\u51f9\u9677\u6027\u6c34\u80bf\u3002<\/span><\/p>\n


<\/p>\n

\u8f85\u52a9\u68c0\u67e5<\/span><\/strong><\/span><\/p>\n


<\/p>\n

\u8840\u5e38\u89c4\u767d\u7ec6\u80de\u8ba1\u6570 45.56 * <\/span>109<\/sup><\/span><\/strong><\/span> \/L\uff0c\u4e2d\u6027\u7c92\u7ec6\u80de\u767e\u5206\u6bd4 0.91\u3002\u8840\u751f\u5316\uff1a\u5929\u51ac\u6c28\u9178\u6c28\u57fa\u8f6c\u79fb\u9176 104.6 U\/L\uff0c\u03b3-\u8c37\u6c28\u9170\u8f6c\u80bd\u9176 77.5 U\/L\uff0c\u5c3f\u7d20 38.97 mmol\/L\uff0c\u808c\u9150 216.4 umol\/L\uff0c\u808c\u9178\u6fc0\u9176 1295 U\/L\uff0c\u808c\u9178\u6fc0\u9176\u540c\u5de5\u9176 64.9 ng\/ml\uff0c\u4e73\u9178\u8131\u6c22\u9176 1393 U\/L\uff0c\u808c\u7ea2\u86cb\u767d 944.9 ng\/ml\uff0c\u5168\u8840\u808c\u9499\u86cb\u767d 19.8 ng\/ml\uff0c\u8111\u5229\u94a0\u80bd\u524d\u4f53\uff08Pro BNP\uff0910490 pg\/ml\uff0cD-\u4e8c\u805a\u4f53 10.86 ug\/ml\uff0c\u767d\u7ec6\u80de\u4ecb\u7d20-6\uff08IL-6\uff091278 pg\/ml\uff0c\u964d\u9499\u7d20\u539f 20.23 ng\/ml\u3002\u52a8\u8109\u8840\u6c14\u793a \u2160 \u578b\u547c\u8870\u5408\u5e76\u4ee3\u8c22\u6027\u9178\u4e2d\u6bd2\u3002<\/span><\/p>\n


<\/p>\n

\uff08\u4ee5\u4e0b\u56fe\u7247\u53ef\u80fd\u5f15\u8d77\u4e0d\u9002\uff0c\u975e\u533b\u5b66\u4e13\u4e1a\u4eba\u58eb\u8bf7\u8fc5\u901f\u64a4\u79bb\uff09<\/span><\/p>\n


<\/p>\n

\u2193\u2193<\/span><\/p>\n


<\/p>\n

\u2193\u2193<\/span><\/p>\n


<\/p>\n

\u2193\u2193<\/span><\/p>\n


<\/p>\n

\u2193\u2193<\/span><\/p>\n


<\/p>\n

\u2193\u2193<\/span><\/p>\n


<\/p>\n

\u2193\u2193<\/span><\/p>\n


<\/p>\n

\u2193\u2193<\/span><\/p>\n


<\/p>\n

\u2193\u2193<\/span><\/p>\n


<\/p>\n

\u2193\u2193<\/span><\/p>\n


<\/p>\n

\u2193\u2193<\/span><\/p>\n


<\/p>\n

\"\u4e45\u75c5\u6210\u533b\uff1f\u60a3\u8005\u81ea\u884c\u8054\u7528\u9776\u5411\u836f\u8eab\u4ea1\uff01\"<\/p>\n

\n
\n
\n
\n
\n
\n
\n
\n
\n
\n

\u25b3 \u7d2f\u53ca\u56db\u80a2\u7684\u5e7f\u6cdb\u76ae\u635f<\/span><\/p>\n


<\/p>\n

\"\u4e45\u75c5\u6210\u533b\uff1f\u60a3\u8005\u81ea\u884c\u8054\u7528\u9776\u5411\u836f\u8eab\u4ea1\uff01\"<\/p>\n

\u25b3 \u5fc3\u7535\u56fe\uff1a\u7aa6\u6027\u5fc3\u52a8\u8fc7\u901f\uff0cV2\u3001V3\u3001V4\u3001V5\u5e7f\u6cdbST\u6bb5\u5f13\u80cc\u578b\u62ac\u9ad8\u3002\u65e2\u5f80\u4e24\u79cd\u9776\u5411\u836f\u7269\u90fd\u6709\u5fc3\u810f\u6bd2\u6027\u7684\u62a5\u9053\uff0c\u5c1a\u4e0d\u80fd\u6392\u9664\u9776\u5411\u836f\u7269\u5acc\u7591\u3002<\/span><\/p>\n


<\/p>\n

\"\u4e45\u75c5\u6210\u533b\uff1f\u60a3\u8005\u81ea\u884c\u8054\u7528\u9776\u5411\u836f\u8eab\u4ea1\uff01\"<\/p>\n

\u25b3 \u80f8\u90e8CT\u5e73\u626b\uff1a\u53f3\u80ba\u4e0a\u53f6\u4e2d\u592e\u578b\u80ba\u764c\u5e76\u7eb5\u8188\u6dcb\u5df4\u7ed3\u8f6c\u79fb\uff0c\u53cc\u80ba\u5e7f\u6cdb\u708e\u6027\u75c5\u53d8\uff0c\u53f3\u4fa7\u80f8\u8154\u79ef\u6db2\u4f34\u4e0b\u80ba\u81a8\u80c0\u4e0d\u5168\u3002<\/span><\/p>\n


<\/p>\n

\u5165\u9662\u8bca\u65ad<\/span><\/strong><\/p>\n


<\/p>\n

    \n
  1. \n

    \u53d1\u70ed\u4f34\u5168\u8eab\u7600\u6591\u539f\u56e0\u5f85\u67e5\uff1b<\/span><\/p>\n<\/li>\n

  2. \n

    \u6025\u6027\uff08\u524d\u58c1\uff09\u5fc3\u808c\u6897\u6b7b \u5fc3\u529b\u8870\u7aed\uff08Killip \u2163 \u7ea7\uff09\uff1b<\/span><\/p>\n<\/li>\n

  3. \n

    \u7d2b\u765c\u578b\u836f\u75b9\uff1b<\/span><\/p>\n<\/li>\n

  4. \n

    \u53f3\u80ba\u817a\u764c\uff08cT4NxM1c\uff0c\u2163 \u671f\uff09 \u8111\u8f6c\u79fb\u7076\u5207\u9664\u672f\u540e\uff0c\u809d\u8f6c\u79fb\uff0c\u5168\u8eab\u591a\u53d1\u6dcb\u5df4\u7ed3\u8f6c\u79fb\uff0c\u53f3\u4fa7\u80f8\u8154\u79ef\u6db2\u4f34\u4e0b\u80ba\u81a8\u80c0\u4e0d\u5168\uff1b<\/span><\/p>\n<\/li>\n

  5. \n

    \u80ba\u90e8\u611f\u67d3\u4f34\u95f4\u8d28\u6027\u80ba\u708e\u4e0d\u9664\u5916\uff1b<\/span><\/p>\n<\/li>\n

  6. \n

    \u2160 \u578b\u547c\u8870\u5408\u5e76\u4ee3\u8c22\u6027\u9178\u4e2d\u6bd2\uff1b<\/span><\/p>\n<\/li>\n

  7. \n

    \u6025\u6027\u809d\u80be\u529f\u80fd\u4e0d\u5168\uff1b<\/span><\/p>\n<\/li>\n

  8. \n

    \u9ad8\u8840\u538b\u75c5<\/span><\/p>\n<\/li>\n<\/ol>\n


    <\/p>\n

    \u56e0\u60a3\u8005\u5bb6\u5c5e\u62d2\u7edd\u6709\u521b\u548c\u4fb5\u5165\u6027\u64cd\u4f5c\u4e0e\u6551\u6cbb\u624b\u6bb5\uff0c\u6545\u5165\u9662\u540e\u7ed9\u4e88\u79ef\u6781\u5bf9\u75c7\u652f\u6301\u6cbb\u7597\uff0c\u4f46\u6548\u679c\u4e0d\u660e\u663e\u3002\u60a3\u8005\u7ec8\u56e0\u547c\u5438\u5faa\u73af\u8870\u7aed\u4e8e\u5165\u9662\u540e\u7b2c 2 \u65e5\u6b7b\u4ea1\u3002<\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n


    <\/p>\n


    <\/p>\n

    \u30fb\u30fb\u30fb<\/span><\/strong><\/strong><\/span><\/p>\n


    <\/span><\/strong><\/strong><\/span><\/p>\n

    \u8ba8\u8bba<\/strong><\/span><\/p>\n

    \u60a3\u8005\u65e2\u5f80\u4e00\u822c\u8eab\u4f53\u72b6\u51b5\u826f\u597d\uff0c\u4ec5\u957f\u671f\u53e3\u670d\u964d\u538b\u836f\uff0c\u65e0\u76ae\u80a4\u75c5\u53f2\uff0c\u4e5f\u672a\u660e\u786e\u6709\u5fc3\u3001\u809d\u548c\u80be\u75be\u60a3\uff0c\u65e0\u6cd5\u7528\u5355\u7eaf\u7684\u75be\u75c5\u8fdb\u5c55\u4e88\u4ee5\u5408\u7406\u89e3\u91ca\u5176\u77ed\u65f6\u95f4\u5185\u5927\u9762\u79ef\u76ae\u635f\u548c\u809d\u80be\u529f\u80fd\u5f02\u5e38\u7684\u73b0\u8c61\uff0c\u6545\u8ba4\u4e3a\u4e0e\u6b64\u6b21\u672a\u9075\u533b\u5631\u7528\u836f\u6709\u5f88\u5927\u5173\u8054\u6027\u3002<\/span>
    <\/p>\n


    <\/p>\n

    \u6b64\u5916\uff0c\u53cc\u80ba\u7684\u5e7f\u6cdb\u708e\u6027\u75c5\u53d8\u5c1a\u4e0d\u80fd\u6392\u9664\u9776\u5411\u836f\u7269\u6240\u81f4\u95f4\u8d28\u6027\u80ba\u75c5\u548c\uff08\u6216\uff09\u5408\u5e76\u611f\u67d3\u7684\u53ef\u80fd\u3002<\/span><\/p>\n


    <\/p>\n

    \u65e2\u5f80\u5384\u6d1b\u66ff\u5c3c\u7528\u4e8e\u665a\u671f EGFR \u7a81\u53d8\u9633\u6027\u7684\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08NSCLC\uff09\u4e00\u7ebf\u6cbb\u7597\u3002\u6700\u5e38\u89c1\u7684\u4e0d\u826f\u53cd\u5e94\u662f\u76ae\u75b9\u548c\u8179\u6cfb\uff0c\u591a\u6570\u7684\u76ae\u75b9\u53d1\u751f\u4e8e\u670d\u836f 2 \u5468\u5185\u3002\u65e2\u5f80\u5df2\u6709\u5927\u75b1\u6027\uff0c\u6c34\u6ce1\u6027\u548c\u5265\u8131\u6027\u76ae\u80a4\u6539\u53d8\u7684\u62a5\u9053\u3002\u5361\u535a\u66ff\u5c3c\u662f\u591a\u79cd\u916a\u6c28\u9178\u6fc0\u9176\u53d7\u4f53\u7684\u62ee\u6297\u5242\uff0c\u540c\u65f6\u4e5f\u662f\u591a\u9776\u70b9\u4f5c\u7528\u7684\u5206\u5b50\u9776\u5411\u836f\uff0c\u5177\u6709\u53d1\u6325\u80bf\u7624\u3001\u51cf\u5c11\u8f6c\u79fb\u5e76\u6291\u5236\u80bf\u7624\u8840\u7ba1\u65b0\u751f\u7b49\u4f5c\u7528\uff0c\u88ab\u79f0\u4e3a\u300c\u6297\u764c\u591a\u9762\u624b\u300d\u3002\u5728\u5384\u6d1b\u66ff\u5c3c\u8054\u5408\u5361\u535a\u66ff\u5c3c\u7684\u2160b \/ \u2161 \u671f\u4e34\u5e8a\u8bd5\u9a8c\uff08NCT00596648\uff09\u660e\u786e\u4e86\u53cc\u9776\u6cbb\u7597\u7684\u89c4\u8303\u670d\u7528\u65b9\u6cd5\uff1a\u5361\u535a\u66ff\u5c3c 100 mg \u548c\u5384\u6d1b\u66ff\u5c3c 50 mg qd \u6216\u5361\u535a\u66ff\u5c3c 40 mg \u548c\u5384\u6d1b\u66ff\u5c3c 150 mg qd \u7684\u6a21\u5f0f\u3002<\/span><\/p>\n


    <\/p>\n

    \u5982\u4eca\uff0c\u8d8a\u6765\u8d8a\u591a\u7684\u9776\u5411\u836f\u7269\u7814\u53d1\u6210\u529f\u548c\u4e0a\u5e02\uff0c\u800c\u5728\u4e0a\u5e02\u524d\u7684\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u96be\u4ee5\u5168\u9762\u89c2\u5bdf\u5230\u6216\u660e\u786e\u77e5\u6653\u5176\u4e0d\u826f\u53cd\u5e94\u548c\u6bd2\u6027\u53cd\u5e94\uff0c\u5176\u4f1a\u968f\u7740\u4e34\u5e8a\u5e94\u7528\u9010\u6b65\u53d1\u73b0\u3002<\/span><\/p>\n


    <\/p>\n

    \u7efc\u4e0a\u6240\u8ff0\uff0c\u867d\u7136\u80bf\u7624\u60a3\u8005\u672c\u4eba\u548c\u5bb6\u5c5e\u666e\u904d\u6709\u7126\u8651\u3001\u7d27\u5f20\u3001\u65e0\u52a9\u548c\u4e0d\u77e5\u6240\u63aa\u7684\u5fc3\u60c5\uff0c\u8fd9\u6211\u4eec\u90fd\u80fd\u7406\u89e3\uff0c\u4f46\u5343\u4e07\u4e0d\u80fd\u5c06\u6b64\u5fc3\u60c5\u8f6c\u5316\u4e3a\u6709\u75c5\u4e71\u6295\u533b\u6216\u8005\u767e\u75c5\u4e4b\u540e\u81ea\u5df1\u5c31\u662f\u6c5f\u6e56\u90ce\u4e2d\u7684\u5177\u4f53\u884c\u52a8\uff0c\u66f4\u4e0d\u80fd\u542c\u300c\u522b\u4eba\u7684\u7ecf\u9a8c\u300d\u3002<\/span><\/p>\n


    <\/p>\n

    \u4f5c\u4e3a\u533b\u751f\uff0c\u6211\u4eec\u5e94\u544a\u8beb\u60a3\u8005\uff0c\u5bf9\u4e8e\u4efb\u4f55\u6297\u80bf\u7624\u7684\u6cbb\u7597\u5e94\u5145\u5206\u6c9f\u901a\uff0c\u5e76\u4e86\u89e3\u5728\u6cbb\u7597\u8fc7\u7a0b\u4e2d\u53ef\u80fd\u51fa\u73b0\u7684\u98ce\u9669\u548c\u9884\u9632\u63aa\u65bd\u3002\u4e0d\u53ef\u56e0\u75c5\u968f\u610f\u3001\u76f2\u76ee\u7684\u4f7f\u7528\u9776\u5411\u836f\u7269\uff0c\u6bd5\u7adf\u6211\u4eec\u7684\u8eab\u4f53\u4e0d\u662f\u5927\u8bd5\u7ba1\uff0c\u53ef\u4ee5\u968f\u610f\u914d\u4f0d\u8bd5\u5242\u89c2\u5bdf\u836f\u7269\u7684\u53cd\u5e94\u6548\u679c\u3002<\/span>\uff08\u7f16\u8f91\uff1a\u6c5f\u5c0f\u5154 \u6676\u6676\u738b <\/span>\uff09<\/span><\/p>\n


    <\/p>\n

    \n
    \n
    \n

    \u5bf9\u4e8e\u4e0a\u8ff0\u6848\u4f8b\uff0c\u4f60\u600e\u4e48\u770b\uff1f\u4e34\u5e8a\u5de5\u4f5c\u4e2d\uff0c\u4f60\u8fd8\u7ecf\u5386\u8fc7\u54ea\u4e9b\u8ba9\u4eba\u54ed\u7b11\u4e0d\u5f97\u7684\u60a3\u8005\u6545\u4e8b\uff1f\u6b22\u8fce\u5728\u8bc4\u8bba\u533a\u7559\u8a00\u4ea4\u6d41\u3002<\/span><\/p>\n<\/section>\n


    <\/section>\n<\/section>\n<\/section>\n


    <\/p>\n

    \u672c\u6587\u9996\u53d1\u4e8e\u4e01\u9999\u56ed\u65d7\u4e0b\u516c\u4f17\u53f7\u300c\u80bf\u7624\u65f6\u95f4\u300d<\/span><\/p>\n

    \n

    \"\u4e45\u75c5\u6210\u533b\uff1f\u60a3\u8005\u81ea\u884c\u8054\u7528\u9776\u5411\u836f\u8eab\u4ea1\uff01\"<\/p>\n

    \n

    \n
    \n
    \n
    \n
    \n
    \n
    \n
    \n

    \u53c2\u8003\u6587\u732e\uff1a<\/p>\n

    1. BoeckS, Hausmann A, Reibke R, et al. Severe lung and skin toxicity during treatmentwith gemcitabine and erlotinib for metastatic pancreatic cancer.[J].Anti-cancer drugs, 2007, 18(9):1109-1111.<\/span><\/p>\n

    2. P\u00e9rezsolerR, Chachoua A, Hammond L A, et al. Determinants of tumor response and survivalwith erlotinib in patients with non–small-cell lung cancer.[J]. Journal ofClinical Oncology, 2004, 22(16):3238-3247.<\/span><\/p>\n

    3. \u7279\u7f57\u51ef-\u76d0\u9178\u5384\u6d1b\u66ff\u5c3c\u7247\u836f\u54c1\u8bf4\u660e\u4e66.2006\u5e74\u7248.\u4e0a\u6d77\u7f57\u6c0f\u5236\u836f\u6709\u9650\u516c\u53f8.<\/span><\/p>\n

    4. \u5b97\u6653\u798f,\u8c22\u6797\u8273,\u9646\u5a07,\u738b\u6167,\u674e\u7530,\u9ec4\u8302,\u5468\u6797\u798f.\u5384\u6d1b\u66ff\u5c3c\u81f4\u91cd\u5ea6\u76ae\u75b9\u548c\u81f4\u6b7b\u6027\u95f4\u8d28\u6027\u80ba\u75c5\u4e00\u4f8b\u4e34\u5e8a\u5206\u6790[J].\u4e2d\u56fd\u547c\u5438\u4e0e\u5371\u91cd\u76d1\u62a4\u6742\u5fd7,2014,13(03):273-276.<\/span><\/p>\n

    5. Jost M, KariC, Rodeck U. The EGF receptor – an essential regulator of multiple epidermalfunctions.[J]. European Journal of Dermatology, 2000, 10(7):505-510.<\/span><\/p>\n

    6. SaifM,Merikas I,Tsimboukis S,et al. Erlotinib \u2013induced skin rash.Pathogenesis, clinicalsignifi cancer and management in pancreatic cancer patients[J].Pancreas, 2008,9(3):267-274.<\/span><\/p>\n

    7. BoeckS, Hausmann A, Reibke R, et al. Severe lung and skin toxicity during treatmentwith gemcitabine and erlotinib for metastatic pancreatic cancer.Anti-Cancer Drugs,2007, 18(9): 1109-1111.<\/span><\/p>\n

    8. \u4e01\u71d5,\u5218\u8c26,\u5357\u5a1f,\u5468\u6e05\u534e.\u5384\u6d1b\u66ff\u5c3c\u5f15\u8d77\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u60a3\u8005\u53d1\u751f\u76ae\u75b9\u7684\u75c5\u7406\u673a\u5236\u3001\u4e34\u5e8a\u610f\u4e49\u53ca\u5176\u6cbb\u7597[J].\u4e2d\u56fd\u80ba\u764c\u6742\u5fd7,2009,12(12):1330-1336.<\/span><\/p>\n

    9. \u9648\u6653\u971e,\u5b59\u8f89,\u5f20\u73b2,\u5b59\u5b87\u840d,\u5468\u5f69\u5b58.\u76d0\u9178\u5384\u6d1b\u66ff\u5c3c\u6240\u81f4\u76ae\u75b9\u7684\u514d\u75ab\u673a\u5236\u7814\u7a76[J].\u80bf\u7624,2011,31(6):542-545.<\/span><\/p>\n

    10. WackerB, Nagrani T, Weinberg J, et al. Correlation between development of rash andefficacy in patients treated with the epidermal growth factor receptor tyrosinekinase inhibitor erlotinib in two large phase III studies[J]. Clinical CancerResearch An Official Journal of the American Association for Cancer Research,2007, 13(13):3913-3921.<\/span><\/p>\n

    11. \u9ec4\u9038\u751f,\u6768\u887f\u8bb0,\u6768\u8273,\u9ec4\u7389\u5a1f,\u5ed6\u65e5\u5f3a,\u5434\u4e00\u9f99.\u76ae\u75b9\u4e0e\u5384\u6d1b\u66ff\u5c3c\u6cbb\u7597\u665a\u671f\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u7597\u6548\u76f8\u5173\u6027\u7814\u7a76[J].\u4e2d\u56fd\u764c\u75c7\u6742\u5fd7,2009,19(9):689-692.<\/span><\/p>\n

    12. \u5d14\u8fea,\u5d14\u4fca\u660c,\u9648\u826f\u5b89,\u89e3\u7acb\u65b0.\u5384\u6d1b\u66ff\u5c3c\u5355\u836f\u6cbb\u7597\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u7ee7\u53d1\u91cd\u75c7\u80ba\u7ea4\u7ef4\u5316\u4e00\u4f8b[J].\u4e2d\u534e\u5185\u79d1\u6742\u5fd7,2008,47(2):151.<\/span><\/p>\n

    13. YakesF M, Chen J, Tan J, et al. Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor,Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth[J]. MolecularCancer Therapeutics, 2011, 10(12): 2298 -2308.<\/span><\/p>\n

     14. Viola D, Cappagli V, Elisei R.Cabozantinib (XL184) for the treatment of locally advanced or metastaticprogressive medullary thyroid cancer[J]. Future Oncology, 2013, 9(8):1083-1092.<\/span><\/p>\n

    15. BentzienF, Zuzow M, Heald N, et al. In vitro and in vivo activity of cabozantinib(XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroidcancer.[J]. Thyroid Official Journal of the American Thyroid Association, 2013,23(12):1569-1577.<\/span><\/p>\n

    16. EngelmanJA; Zejnullahu K; Mitsudomi T; Song Y; Hyland C; Park JO; Lindeman N; Gale CM;Zhao X; Christensen J; Kosaka T; Holmes AJ; Rogers AM; Cappuzzo F; Mok T; LeeC; Johnson BE; Cantley LC; J\u00e4nne PA. MET Amplification Leads to GefitinibResistance in Lung Cancer by Activating ERBB3 Signaling[J]. Science, 2007,316(5827):1039-1043.<\/span><\/p>\n

    17. JackmanD, Pao W, Riely G J, et al. Clinical definition of acquired resistance toepidermal growth factor receptor tyrosine kinase inhibitors in non-small-celllung cancer.[J]. Journal of Clinical Oncology, 2010, 28(2):357-360.<\/span><\/p>\n

    18. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapyas first-line treatment for European patients with advanced EGFRmutation-positive non-small-cell lung cancer (EURTAC): a multicentre,open-label, randomised phase 3 trial.[J]. Lancet Oncology, 2012, 13(3):239-246.<\/span><\/p>\n

    19. SetoT, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-linetherapy in patients with advanced non-squamous non-small-cell lung cancerharbouring EGFR mutations (JO25567): an open-label, randomised, multicentre,phase 2 study.[J]. Lancet Oncology, 2014, 15(11):1236.<\/span><\/p>\n

    20. BustinF, Flynn P, Hart L, et al. Efficacy of bevacizumab plus erlotinib versuserlotinib alone in advanced non-small-cell lung cancer after failure ofstandard first-line chemotherapy (BeTa): a double-blind, placebo-controlled,phase 3 trial[J]. Lancet, 2011, 377(9780):1846-1854.<\/span><\/p>\n

    21. YanoS, Wang W, Li Q, et al. Hepatocyte growth factor induces gefitinib resistanceof lung adenocarcinoma with epidermal growth factor receptor-activating mutations.[J].CancerResearch, 2008, 68 (22):9479 – 9487.<\/span><\/p>\n

    22. TangZ, Du R, Jiang S, et al. Dual MET\u2013EGFR combinatorial inhibition againstT790M-EGFR-mediated erlotinib-resistant lung cancer[J]. British Journal ofCancer, 2008, 99(6):911-922.<\/span><\/p>\n

    23. MasuyaD, Huang C, Liu D, et al. Masuya D, Huang C, Liu D, Nakashima T, Kameyama K,Haba R, Ueno M, Yokomise HThe tumour-stromal interaction between intratumoralc-Met and stromal hepatocyte growth factor associated with tumour growth andprognosis in non-small-cell lung cancer patients[J]. British Journal of Cancer,2004, 90(8):1555-1562.<\/span><\/p>\n

    24. Neal J W, Dahlberg S E, Wakelee H A, et al. Erlotinib,cabozantinib, or erlotinib plus cabozantinib as second- or third-line treatmentof patients withEGFRwild-type advanced non-small cell lung cancer (ECOG-ACRIN1512): a phase 2 randomised controlled trial:[J]. Lancet Oncology, 2016,17(12):1661-1671.<\/span><\/p>\n

    25. WakeleeH A, Gettinger S, Engelman J, et al. A phase Ib\/II study of cabozantinib(XL184) with or without erlotinib in patients with non-small cell lungcancer[J]. Cancer Chemotherapy & Pharmacology, 2017, 79(5):1-10.<\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section><\/div>\n","protected":false},"excerpt":{"rendered":"

    \u4e00\u4f4d\u610f\u8bc6\u4e0d\u6e05\uff0c\u80f8\u95f7\u618b\u6c14\uff0c\u5168\u8eab\u76ae\u80a4\u51fa\u73b0\u5927\u9762\u79ef\u6697\u7d2b\u7ea2\u8272\u7600\u6591\u7684\u60a3\u8005\u6765\u5230\u4e86\u6025\u8bca\u79d1\u3002 \u8be2\u95ee\u75c5\u53f2\u53d1\u73b0\uff0c\u65e2\u5f80\u6709\u80ba\u817a\u764c\u8111\u90e8\u8f6c\u79fb […]<\/p>\n","protected":false},"author":1,"featured_media":50627,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[2],"tags":[],"_links":{"self":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/50626"}],"collection":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/comments?post=50626"}],"version-history":[{"count":1,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/50626\/revisions"}],"predecessor-version":[{"id":50633,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/50626\/revisions\/50633"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media\/50627"}],"wp:attachment":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media?parent=50626"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/categories?post=50626"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/tags?post=50626"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}